Pacific Biosciences of California’s (PACB) Buy Rating Reaffirmed at Canaccord Genuity Group

Pacific Biosciences of California (NASDAQ:PACB – Get Free Report)‘s stock had its “buy” rating restated by stock analysts at Canaccord Genuity Group in a research note issued to investors on Thursday,Benzinga reports. They currently have a $3.00 price objective on the biotechnology company’s stock. Canaccord Genuity Group’s target price indicates a potential upside of 120.59% […]